SAB Biotherapeutics
Latest round
- Series B
Last raised
- Jul 2020
Total raised
- $26M
Investors
- 2
About SAB Biotherapeutics
SAB Biotherapeutics, Inc.SAB Biotherapeutics, Inc. was founded in 2014 in Sioux Falls, US. The company is focused on the creation of advanced therapies that address immune disorders. Eddie Sullivan is the CEO and co-founder, with a goal to expand their treatment offerings., valuing the transaction at approximately USD 30 mn. This merger allowed the company to be publicly listed on Nasdaq under the ticker symbols "SABS" and "SABSW" from October 25, 2021., Inc.SAB Biotherapeutics specializes in developing immunotherapies for immune and autoimmune disorders, particularly targeting type 1 diabetes (T1D). The primary product, SAB-142, is designed to alter disease progression by modulating the immune response that damages insulin-producing beta cells in the pancreas.In 2023, SAB Biotherapeutics reported revenue of USD 2,238,991 with an EBITDA of USD -34,330,038. The company aims to introduce new products focused on treating autoimmune disorders while targeting expansion into markets across Europe and Asia by late 2024.5 mn government awards, alongside USD 27 mn from prior awards, will support these initiatives. The merger with Big Cypress Acquisition Corp. will also facilitate further growth and development of their immunotherapy strategies.
Who invested in SAB Biotherapeutics
2 investors across 2 rounds
See all investors in SAB Biotherapeutics
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about SAB Biotherapeutics
Who invested in SAB Biotherapeutics?
SAB Biotherapeutics has 2 investors on record across 2 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has SAB Biotherapeutics raised?
SAB Biotherapeutics has raised 2 venture rounds. Sign up free to see how much each round raised and the total.
When did SAB Biotherapeutics last raise money?
SAB Biotherapeutics's most recent round on record is a Series B, in Jul 2020.
What does SAB Biotherapeutics do?
SAB Biotherapeutics is a pharmaceuticals company.
Where is SAB Biotherapeutics headquartered?
SAB Biotherapeutics is headquartered in Sioux Falls, US.
Which VCs invest in companies like SAB Biotherapeutics?
Among active investors with capital left to deploy, Andreessen Horowitz, Founders Fund, Accel and Thrive Capital back pharmaceuticals companies at SAB Biotherapeutics's stage. Their profiles are linked below.
VCs backing pharmaceuticals startups at Series B
Raising like SAB Biotherapeutics? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.